(90)Y/(177)Lu-DOTATOC: From Preclinical Studies to Application in Humans

The PRRT (Peptide Receptor Radionuclide Therapy) is a promising modality treatment for patients with inoperable or metastatic neuroendocrine tumors (NETs). Progression-free survival (PFS) and overall survival (OS) of these patients are favorably comparable with standard therapies. The protagonist in...

Descripción completa

Detalles Bibliográficos
Autores principales: Uccelli, Licia, Boschi, Alessandra, Cittanti, Corrado, Martini, Petra, Panareo, Stefano, Tonini, Eugenia, Nieri, Alberto, Urso, Luca, Caracciolo, Matteo, Lodi, Luca, Carnevale, Aldo, Giganti, Melchiore, Bartolomei, Mirco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469896/
https://www.ncbi.nlm.nih.gov/pubmed/34575538
http://dx.doi.org/10.3390/pharmaceutics13091463
Descripción
Sumario:The PRRT (Peptide Receptor Radionuclide Therapy) is a promising modality treatment for patients with inoperable or metastatic neuroendocrine tumors (NETs). Progression-free survival (PFS) and overall survival (OS) of these patients are favorably comparable with standard therapies. The protagonist in this type of therapy is a somatostatin-modified peptide fragment ([Tyr3] octreotide), equipped with a specific chelating system (DOTA) capable of creating a stable bond with β-emitting radionuclides, such as yttrium-90 and lutetium-177. In this review, covering twenty five years of literature, we describe the characteristics and performances of the two most used therapeutic radiopharmaceuticals for the NETs radio-treatment: [(90)Y]Y-DOTATOC and [(177)Lu]Lu-DOTATOC taking this opportunity to retrace the most significant results that have determined their success, promoting them from preclinical studies to application in humans.

Ejemplares similares